摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(2-chloro-10H-phenothiazin-10-yl)-N-isopropyl-N,N-dimethylpropan-1-aminium bromide | 153871-19-3

中文名称
——
中文别名
——
英文名称
3-(2-chloro-10H-phenothiazin-10-yl)-N-isopropyl-N,N-dimethylpropan-1-aminium bromide
英文别名
N-[3-(2-chlorophenothiazin-10-yl)propyl] dimethylisopropylammonium bromide;3-(2-Chlorophenothiazin-10-yl)propyl-dimethyl-propan-2-ylazanium;bromide
3-(2-chloro-10H-phenothiazin-10-yl)-N-isopropyl-N,N-dimethylpropan-1-aminium bromide化学式
CAS
153871-19-3
化学式
Br*C20H26ClN2S
mdl
——
分子量
441.863
InChiKey
RCEZFXXXWGHFHN-UHFFFAOYSA-M
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.82
  • 重原子数:
    25
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    28.5
  • 氢给体数:
    0
  • 氢受体数:
    3

文献信息

  • [EN] NEW CLASS OF ANTIBIOTICS HAVING LOW MIC-VALUES TOWARDS DIFFERENT STRAINS OF BACTERIA<br/>[FR] NOUVELLE CLASSE D'ANTIBIOTIQUES AYANT DE FAIBLES CONCENTRATIONS MINIMALES INHIBITRICES (CMI) À L'ÉGARD DE DIFFÉRENTES SOUCHES DE BACTÉRIES
    申请人:UNIV COPENHAGEN
    公开号:WO2020216777A1
    公开(公告)日:2020-10-29
    The present invention relates to a composition comprising a compound of formula (I) wherein X is selected from the group consisting of S, Se, P, PO, SO, NR1, CR1, CR1R1 or C0-2-alkyl; Z is selected from the group consisting of hydrogen, a halogen, SR4, OR4, COR4 where R4 is a C1-12-alkyl; each R2 is independently selected from the group consisting of C1-6-alkyl, halogen, C3-8-cycloalkyl, OH, NH2, NHR1, N(R1)2, O-C1-6-alkyl, O-C3-8-cycloalkyl, NH-C1-6-alkyl, NH-C3-8- cycloalkyl, S-C1-6-alkyl, S-C3-8-cycloalkyl, aryl, heteroaryl, aryloxy, heteroaryloxy, arylamino, heteroarylamino, arylalkyl, heteroarylalkyl, arylalkyloxy and heteroarylalkyloxy; d is selected from 0, 1, 2, and 3; each R3 is independently selected from the group consisting of C1-6-alkyl, halogen, C3-8-cycloalkyl, OH, NH2, NHR1, N(R1)2, O-C1-6-alkyl, O-C3-8-cycloalkyl, NH-C1-6-alkyl, NH-C3-8-cycloalkyl, S-C1-6-alkyl, S-C3-8-cycloalkyl, aryl, heteroaryl, aryloxy, heteroaryloxy, arylamino, heteroarylamino, arylalkyl, heteroarylalkyl, arylalkyloxy and heteroarylalkyloxy; e is selected from 0, 1, 2, 3, and 4; R1 is selected from the group consisting of C1-6-alkyl, C3-8-cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl; R5 is N-(CHW)-N(Y1)(Y2)(Y3) or C=CH-(CHW)-N(Y1)(Y2)(Y3); each W is individually selected from the group consisting of linear or branched C1-6-alkyl or together with the nitrogen atom - N(Y1)(Y2)(Y3) - to which it is attached forms an optionally substituted nitrogen-containing heteroaryl or optionally substituted nitrogen-containing heterocyclyl together with Y1 where; Y1 is selected from the group consisting of C1-12-alkyl or together with the W and the nitrogen atom to which it is attached forms an optionally substituted nitrogen-containing heteroaryl or optionally substituted nitrogen-containing heterocyclyl; Y2 is selected from the group consisting of C1-12-alkyl; Y3 is selected from the group consisting of linear or branched C2-25-alkyl, linear or branched C2-25 alkenyl or linear or branched C2-25 alkynyl; where A is selected from any pharmaceutical relevant/acceptable anion/counterion; wherein if X is S and Z is a halogen then Y3 cannot be a C2-alkyl or a branched C3-alkyl; wherein if X is S and Z is hydrogen then Y3 cannot be C2-alkyl or linear or branched C5-alkyl. The invention also relates to anti-microbial composition for use as a medicament and for use in treating a microbial infection in a human subject.
    本发明涉及一种组合物,该组合物包括以下式(I)的化合物,其中X从S、Se、P、PO、SO、NR1、CR1、CR1R1或C0-2-烷基组成的群中选择;Z从氢、卤素、SR4、OR4、COR4选择,其中R4是C1-12-烷基;每个R2独立地从C1-6-烷基、卤素、C3-8-环烷基、OH、NH2、NHR1、N(R1)2、O-C1-6-烷基、O-C3-8-环烷基、NH-C1-6-烷基、NH-C3-8-环烷基、S-C1-6-烷基、S-C3-8-环烷基、芳基、杂环芳基、芳氧基、杂芳氧基、芳基基、杂芳基基、芳基烷基、杂芳基烷基、芳基氧基和杂芳基氧基组成的群中选择;d从0、1、2和3中选择;每个R3独立地从C1-6-烷基、卤素、C3-8-环烷基、OH、NH2、NHR1、N(R1)2、O-C1-6-烷基、O-C3-8-环烷基、NH-C1-6-烷基、NH-C3-8-环烷基、S-C1-6-烷基、S-C3-8-环烷基、芳基、杂环芳基、芳氧基、杂芳氧基、芳基基、杂芳基基、芳基烷基、杂芳基烷基、芳基氧基和杂芳基氧基组成的群中选择;e从0、1、2、3和4中选择;R1从C1-6-烷基、C3-8-环烷基、芳基、杂环芳基、芳基烷基、杂芳基烷基组成的群中选择;R5是N-(CHW)-N(Y1)(Y2)(Y3)或C=CH-(CHW)-N(Y1)(Y2)(Y3);每个W单独从线性或支链的C1-6-烷基组成的群中选择,或者与氮原子-N(Y1)(Y2)(Y3)-形成一个可选择取代的含氮杂芳基或可选择取代的含氮杂环烷基,其中;Y1从C1-12-烷基中选择,或者与W和连接的氮原子形成一个可选择取代的含氮杂芳基或可选择取代的含氮杂环烷基;Y2从C1-12-烷基中选择;Y3从线性或支链的C2-25-烷基、线性或支链的C2-25-烯烃基或线性或支链的C2-25-炔烃基中选择;其中A从任何药用相关/可接受的阴离子/对离子中选择;其中如果X是S且Z是卤素,则Y3不能是C2-烷基或支链C3-烷基;其中如果X是S且Z是氢,则Y3不能是C2-烷基或线性或支链的C5-烷基。该发明还涉及用作药物和用于治疗人体主体中的微生物感染的抗微生物组合物。
  • NEW CLASS OF ANTIBIOTICS HAVING LOW MIC-VALUES TOWARDS DIFFERENT STRAINS OF BACTERIA
    申请人:Københavns Universitet
    公开号:US20220313656A1
    公开(公告)日:2022-10-06
    The present invention relates to a composition comprising a compound of formula (I) wherein X is selected from the group consisting of S, Se, P, PO, SO, NR 1 , CR 1 , CR 1 R 1 or C 0-2 -alkyl; Z is selected from the group consisting of hydrogen, a halogen, SR 4 , OR 4 , COR 4 where R 4 is a C 1-12 -alkyl; each R 2 is independently selected from the group consisting of C 1-6 -alkyl, halogen, C 3-8 -cycloalkyl, OH, NH 2 , NHR 1 , N(R 1 ) 2 , O—C 1-6 -alkyl, O—C 3-8 -cycloalkyl, NH—C 1-6 -alkyl, NH—C 3-8 -cycloalkyl, S—C 1-6 -alkyl, S—C 3-8 -cycloalkyl, aryl, heteroaryl, aryloxy, heteroaryloxy, arylamino, heteroarylamino, arylalkyl, heteroarylalkyl, arylalkyloxy and heteroarylalkyloxy; d is selected from 0, 1, 2, and 3; each R 3 is independently selected from the group consisting of C 1-6 -alkyl, halogen, C 3-8 -cycloalkyl, OH, NH 2 , NHR 1 , N(R 1 ) 2 , O—C 1-6 -alkyl, O—C 3-8 -cycloalkyl, NH—C 1-6 -alkyl, NH—C 3-8 -cycloalkyl, S—C 1-6 -alkyl, S-C3-8-cycloalkyl, aryl, heteroaryl, aryloxy, heteroaryloxy, arylamino, heteroarylamino, arylalkyl, heteroarylalkyl, arylalkyloxy and heteroarylalkyloxy; e is selected from 0, 1, 2, 3, and 4; R 1 is selected from the group consisting of C 1-6 -alkyl, C 3-8 -cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl; R 5 is N—(CHW)—N(Y 1 )(Y 2 )(Y 3 ) or C═CH—(CHW)—N(Y 1 )(Y 2 )(Y 3 ); each W is individually selected from the group consisting of linear or branched C 1-6 -alkyl or together with the nitrogen atom —N(Y 1 )(Y 2 )(Y 3 )— to which it is attached forms an optionally substituted nitrogen-containing heteroaryl or optionally substituted nitrogen-containing heterocyclyl together with Y 1 where; Y 1 is selected from the group consisting of C 1-12 -alkyl or together with the W and the nitrogen atom to which it is attached forms an optionally substituted nitrogen-containing heteroaryl or optionally substituted nitrogen-containing heterocyclyl; Y 2 is selected from the group consisting of C 1-12 -alkyl; Y 3 is selected from the group consisting of linear or branched C 2-25 -alkyl, linear or branched C 2-25 alkenyl or linear or branched C 2-25 alkynyl; where A is selected from any pharmaceutical relevant/acceptable anion/counterion; wherein if X is S and Z is a halogen then Y 3 cannot be a C 2 -alkyl or a branched C 3 -alkyl; wherein if X is S and Z is hydrogen then Y 3 cannot be C 2 -alkyl or linear or branched C 5 -alkyl. The invention also relates to anti-microbial composition for use as a medicament and for use in treating a microbial infection in a human subject.
  • US5550143A
    申请人:——
    公开号:US5550143A
    公开(公告)日:1996-08-27
  • US5597819A
    申请人:——
    公开号:US5597819A
    公开(公告)日:1997-01-28
  • US5654323A
    申请人:——
    公开号:US5654323A
    公开(公告)日:1997-08-05
查看更多

同类化合物

()-2-(5-甲基-2-氧代苯并呋喃-3(2)-亚乙基)乙酸乙酯 (双(2,2,2-三氯乙基)) (乙基N-(1H-吲唑-3-基羰基)ethanehydrazonoate) (Z)-3-[[[2,4-二甲基-3-(乙氧羰基)吡咯-5-基]亚甲基]吲哚-2--2- (S)-(-)-5'-苄氧基苯基卡维地洛 (S)-(-)-2-(α-(叔丁基)甲胺)-1H-苯并咪唑 (S)-(-)-2-(α-甲基甲胺)-1H-苯并咪唑 (S)-氨氯地平-d4 (S)-8-氟苯并二氢吡喃-4-胺 (S)-4-(叔丁基)-2-(喹啉-2-基)-4,5-二氢噁唑 (S)-4-氯-1,2-环氧丁烷 (S)-3-(2-(二氟甲基)吡啶-4-基)-7-氟-3-(3-(嘧啶-5-基)苯基)-3H-异吲哚-1-胺 (S)-2-(环丁基氨基)-N-(3-(3,4-二氢异喹啉-2(1H)-基)-2-羟丙基)异烟酰胺 (SP-4-1)-二氯双(喹啉)-钯 (SP-4-1)-二氯双(1-苯基-1H-咪唑-κN3)-钯 (R,S)-可替宁N-氧化物-甲基-d3 (R,S)-六氢-3H-1,2,3-苯并噻唑-2,2-二氧化物-3-羧酸叔丁酯 (R)-(+)-5'-苄氧基卡维地洛 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-卡洛芬 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (R)-4-异丙基-2-恶唑烷硫酮 (R)-3-甲基哌啶盐酸盐; (R)-2-苄基哌啶-1-羧酸叔丁酯 (N-(Boc)-2-吲哚基)二甲基硅烷醇钠 (N-{4-[(6-溴-2-氧代-1,3-苯并恶唑-3(2H)-基)磺酰基]苯基}乙酰胺) (E)-2-氰基-3-(5-(2-辛基-7-(4-(对甲苯基)-1,2,3,3a,4,8b-六氢环戊[b]吲哚-7-基)-2H-苯并[d][1,2,3]三唑-4-基)噻吩-2-基)丙烯酸 (E)-2-氰基-3-[5-(2,5-二氯苯基)呋喃-2-基]-N-喹啉-8-基丙-2-烯酰胺 (8α,9S)-(+)-9-氨基-七氢呋喃-6''-醇,值90% (6R,7R)-7-苯基乙酰胺基-3-[(Z)-2-(4-甲基噻唑-5-基)乙烯基]-3-头孢唑啉-4-羧酸二苯甲基酯 (6-羟基嘧啶-4-基)乙酸 (6,7-二甲氧基-4-(3,4,5-三甲氧基苯基)喹啉) (6,6-二甲基-3-(甲硫基)-1,6-二氢-1,2,4-三嗪-5(2H)-硫酮) (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5R,Z)-3-(羟基((1R,2S,6S,8aS)-1,3,6-三甲基-2-((E)-prop-1-en-1-yl)-1,2,4a,5,6,7,8,8a-八氢萘-1-基)亚甲基)-5-(羟甲基)-1-甲基吡咯烷-2,4-二酮 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-(4-乙氧基-3-甲基苄基)-1,3-苯并二恶茂) (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氯-2,1,3-苯并噻二唑-4-基)-氨基甲氨基硫代甲酸甲酯一氢碘 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (5-氨基-1,3,4-噻二唑-2-基)甲醇 (4aS-反式)-八氢-1H-吡咯并[3,4-b]吡啶 (4aS,9bR)-6-溴-2,3,4,4a,5,9b-六氢-1H-吡啶并[4,3-B]吲哚 (4S,4''S)-2,2''-环亚丙基双[4-叔丁基-4,5-二氢恶唑] (4-(4-氯苯基)硫代)-10-甲基-7H-benzimidazo(2,1-A)奔驰(德)isoquinolin-7一 (4-苄基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4-甲基环戊-1-烯-1-基)(吗啉-4-基)甲酮 (4-己基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4,5-二甲氧基-1,2,3,6-四氢哒嗪)